Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs

NCT06228326 is registered in ClinicalTrials.gov with Krystal Biotech, Inc. as lead sponsor.

NCT NCT06228326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06228326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs
Lead sponsor
Krystal Biotech, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 17, 2024
Completion date
July 31, 2028
Enrollment
250 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, lung cancer (nsclc), lung cancer metastatic, lung cancer, non-small cell, solid tumor, adult